Delivery Order SPE2DB22D2009-SPE2DB25FM0DT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,018.51 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with a completion date of June 3, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,731.88 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price contract was issued on July 25, 2025, with an ultimate completion date of July 28, 2025, and represents a child delivery order under a larger contract vehicle. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,835.76 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with an ultimate completion date of October 29, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The place of performance is AmerisourceBergen's Corporate Office location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,570.78 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed-price delivery order was issued on July 30, 2025, with an ultimate completion date of July 31, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,545.48 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, awarded on July 18, 2025, with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,004.33 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitive award, issued on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a firm fixed-price transaction with no set-aside designation. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters and a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,438.67 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL formulations. This contract, issued on August 22, 2025, with a completion date of August 25, 2025, represents a firm fixed-price delivery order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,278.14 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, and was awarded competitively with no set-aside designation. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,566.65 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, issued on August 28, 2025, with an ultimate completion date of August 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order valued at $5,083.48 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract was competitively awarded with no set-aside designation and utilizes firm fixed-price pricing, with an ultimate completion date of October 24, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply delivery. This delivery order...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM0DTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,837.41 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price contract with no set-aside designation, issued on July 10, 2025, with an ultimate completion date of July 11, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This award represents a single delivery order under AmerisourceBergen's broader relationship with the federal government as a primary pharmaceutical supplier. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vehicle that extends through December 2026. As a leading pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare programs globally, including diabetes medications, specialty pharmaceuticals, vaccines, and medical devices. The company's selection reflects its demonstrated capability to meet federal procurement standards through competitive award processes and its critical role in supporting Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 7/10/25 |